Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8662788 | 0.89 | SNCA (0.35) | SNCA | |
| SCHEMBL8663935 | 0.86 | SNCA (0.32) | SNCA | |
| SCHEMBL16974831 | 0.84 | ALDH1A1 (0.33) | SNCA | |
| SCHEMBL8585922 | 0.83 | NOX1 (0.38) | — | |
| SCHEMBL8582981 | 0.82 | SNCA (0.33) | SNCA | |
| SCHEMBL8662956 | 0.82 | TAAR1 (0.35) | — | |
| SCHEMBL8663744 | 0.82 | TAAR1 (0.35) | — | |
| SCHEMBL8662959 | 0.82 | TAAR1 (0.35) | — | |
| SCHEMBL8526572 | 0.79 | DAPK3 (0.36) | — | |
| SCHEMBL8584957 | 0.79 | DAPK3 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0906297-A1 | 1,2,4-BENZOTHIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-04-07 | — | — | EP | disclosed |
| EP-0853616-A1 | BICYCLIC 4-ARALKYLAMINOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 1998-07-22 | — | — | EP | disclosed |
| WO-1997049689-A1 | BICYCLIC 4-ARALKYLAMINOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997049692-A1 | 1,2,4-BENZOTHIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-12-31 | — | — | WO | disclosed |